On May 16, the 4th Asia Healthcare Summit (ASGH), jointly organized by the Hong Kong SAR Government and the Hong Kong Trade Development Council, was held at the Hong Kong Convention and Exhibition Centre. Under the theme of "Innovation - Inclusion - Effectiveness", the forum covered topics such as challenges and opportunities in the global healthcare industry, the latest developments in medical technology and business opportunities in the Asian healthcare industry, aiming to bring together elites in the global healthcare field to explore ways of innovation and development.

Dr. Xuefeng Yu, Chairman and CEO of CanSinoBio, was invited to attend the event to discuss the prospects and business opportunities of the Asian healthcare industry with policy makers, healthcare experts, scholars, business leaders and investors from all over the world, and to strengthen the communication and cooperation among global healthcare industry participants.

At the conference, Academician Cao Xuetao, Deputy Director of the National Health Commission, mentioned in his special address that the complex changes in the international situation have had a far-reaching impact on global health and safety, human health and well-being, and economic and social development, and that there is a greater need for us to work together to explore new opportunities and meet new challenges in the field of healthcare.

In the subsequent roundtable forum "What's Next in China's Healthcare Arena", participants focused on the public health challenges under the influence of the new crown epidemic, the innovation and development of the vaccine industry, and the expansion of the adult vaccine market. The roundtable discussion centered on public health challenges under the impact of the new crown epidemic, innovation and development of the vaccine industry, and the expansion of the adult vaccine market.

Speaking about the globalization of innovative vaccines in China, Dr. Yu pointed out that the New Crown outbreak has not only led to a deeper public understanding of the importance of public health and vaccination, but also brought unprecedented opportunities for the development of the vaccine industry.

Dr. Yu emphasized the importance of adult vaccine immunization program. So far this year, the number of whooping cough cases in China has increased significantly compared to the same period last year. The lack of adult immunization has become a hidden danger for children to be infected with pertussis and other diseases, while the elderly population with weaker immune systems are also at great risk.

In response to potential market demand, the Company's portfolio of component pertussis products includes Tdcp for adolescents and adults aged 6 years and above. Currently, all subjects have been enrolled in the Phase I clinical trial, and further development plans will be evaluated based on the Phase I phase results. In addition, the Company is also laying out a combination vaccine based on component DPT.

In terms of technology upgrading and vaccines going overseas, Dr. Yu said CanSinoBio has been focusing on the actual needs of the unmet market and is actively exploring diversified modes of cooperation, including product sales licensing, technology transfer, localized production, and R&D cooperation.

Dr. Yu mentioned that CanSinoBio's innovative generation of recombinant polio vaccine, VLP-Polio, has received project funding from the Gates Foundation, and the virus-like particle technology route helps to realize the vision of global polio eradication. The Company is currently the first company in the world to utilize this technology route into the clinic, and expects that we will be able to help eradicate polio globally.

In addition, based on the trial data obtained, the value of the company's mRNA platform, which has been laid out for many years, has been verified, and there is technological support in terms of delivery systems and formulations. CanSinoBio will carry out technology accumulation and extension exploration on the basis of its main business in order to realize a wider application of the mRNA platform. And it will continue to develop combination vaccines, including multiplex and multivalent vaccines, to prepare for new global public health challenges.

Held in conjunction with the 3rd International Healthcare Week, the Summit attracted government officials and organizations in charge of healthcare, international scientific research and medical experts, investors and business leaders from 40 countries and regions around the world.

https://mp.weixin.qq.com/s?__biz=MzI0Nzc5MDU4OQ==&mid=2247495233&idx=1&sn=36d03e45db9041687952000bd857c2af&chksm=e9a800d3dedf89c52504aab696956cef40b9e29488dac1f798e874aa81b1b5f527395f18d448&mpshare=1&scene=1&srcid=0520OmzLfNxNaMxWuHIhbDd9&sharer_shareinfo=be03c48c1776ae16aa681786a76323ca&sharer_shareinfo_first=be03c48c1776ae16aa681786a76323ca#rd